Ocumension Therapeutics (1477.HK)
Ocumension Therapeutics
No. 1858 Yinzhongnan Road
Guoxiang Subdistrict Wuzhong District
Suzhou
China
https://www.ocumension.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 444
Key executives
| Name | Title | Pay | Exercised | Year born |
|---|---|---|---|---|
| Mr. Ye Liu | CEO & Executive Director | 6.42M | N/A | 1972 |
| Dr. Zhaopeng Hu | Chief Development Officer & Executive Director | 2.38M | N/A | 1974 |
| Mr. Tim Ruan | CFO & Joint Company Secretary | N/A | N/A | 1986 |
| Dr. DongHong Chen | Chief Medical Officer | N/A | N/A | 1971 |
| Mr. Qinglei Zuo | Chief Commercial Officer | N/A | N/A | 1984 |
| Ms. Tingchan Chen | Joint Company Secretary | N/A | N/A | 1995 |
Description
Ocumension Therapeutics, together with its subsidiaries, operates as an ophthalmic pharmaceutical platform company in the People's Republic of China. It discovers, develops, and commercializes therapies for ophthalmic patients. The company offers drugs for the treatment of blepharitis, infective and allergic conjunctivitis, dry eye, glaucoma and ocular hypertension, postoperative inflammation, choroidal neovascularization, bacterial conjunctivitis, uveitis, retinitis pigmentosa, acute glaucoma, age-related macular degeneration, cornea graft rejection, myopia, and optic neuritis. It had various drug assets in its portfolio. The company was founded in 2017 and is headquartered in Suzhou, the People's Republic of China.
Corporate governance
Ocumension Therapeutics’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.
